Oct, 1, 2023

Vol.30 No.2, pp. 84-88

Current Issue Archives
Search
Advanced Search
Editorial Office

Review

  • Korean Journal of Biological Psychiatry
  • Volume 4(1); 1997
  • Article

Review

Korean Journal of Biological Psychiatry 1997;4(1):121-6. Published online: Jan, 1, 1997

Abstract PDF Full Text

Changes of Psychopathology and Extrapyramidal Symptoms When Co-administering Fluoxetine and Haloperidol

  • Min-Soo Lee, MD1;Chang-Su Han, MD1;Jae-Won Kim, MD2;Kyung-Sik Won, MD2;and Dong-Il Kwak, MD2;
    1;Department of Neuropsychiatry, College of Medicine, Korea University, Seoul, 2;Department of Psychiatry, Dong-In Hosptal, Pusan, Korea
Abstract

Objectives：The authors have intended to know the drug interaction of fluoxetine and haloperidol when coadministering two drugs to the chronic schizophrenics by assessing the changes of positive, negative symptoms and extrapyramidal symptoms.

Method：We selected 38 patients, the chronic schizophrenics with no physical problems. they are randomly assigned to placebo group and drug group. And then, placebo or fluoxetine 20mg were administered to the subjects of each group during 8 week period. We have assessed their psychopatholgy and extrapyramidal symptoms using Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression(CGI), Simpson-Angus Scale at 0, 2, 4, 6, 8 week during the period.

Results：38 patients have completed the study during 8 weeks. 1) PANSS, CGI：no significant difference between groups and no significant change according to the times. 2) Simpson-Angus Scale：no significant changes.

Conclusion：When co-administering fluoxetine and haloperidol, there were no significant changes of psychopathology and extrapyramidal symptoms. These results suggest that it is safe to coadminister fluoxetine to schizophrenic patients with haloperidol treatmemt.

Keywords Fluoxetine;Haloperidol;Drug interaction.